Form 4: Regulus Therapeutics Director, Jason Nunn, Acquires 60,000 Stock Options

Director Jason Nunn acquired 60,000 stock options in Regulus Therapeutics Inc. on May 20, 2024.

Summary

• On May 20, 2024, Jason Raleigh Nunn, a director of Regulus Therapeutics Inc. (RGLS), acquired 60,000 stock options.
• The exercise price of these options is $2.01.
• The options vest ratably over twelve months, becoming fully vested one year after the grant date or at the company's next annual shareholder meeting, whichever comes first, contingent upon continuous service.
• The expiration date for these options is May 19, 2034.
• Following the transaction, Nunn beneficially owns 60,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a standard transaction (acquisition of stock options) by a company director. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates